Sanofi has been leading several significant operations in the healthcare and pharmaceutical sector recently. For instance, the company is pushing ahead with a
€20bn consumer healthcare spin-off, while also inaugurating
Canada's largest vaccine plant - an initiative forecasted to begin production in 2027. Despite an FDA delay on Sanofi and Regeneron's
Dupixent for COPD, Sanofi's Dupixent fetched an EU regulator's approval for chronic lung disease. In a bid to strengthen its pipeline, Sanofi has also completed the
$1.7bn acquisition of Inhibrx. Moreover, the company has been involved in sizeable collaborations lately, such as the notable one with
Novavax, which led to a vast upsurge in the latter's shares. Sanofi's partnership with OpenAI and Formation Bio to develop AI-backed drugs further validates its commitment to using innovative approaches. Amidst these advancements, the company has faced some legal hiccups - Sanofi and BMS were ordered to pay
$916M in a Plavix marketing case. Furthermore, the company has been investing in Africa's healthcare startups via its Global Health Unit Impact fund, displaying its dedication to global health. Meanwhile, amidst numerous developments, the company has let go of some jobs post a 'full pipeline' shakeup.
Sanofi News Analytics from Fri, 01 Sep 2023 23:17:18 GMT to Sun, 02 Jun 2024 13:00:00 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor 0
